Journey in antithrombotic strategies for ST-elevation myocardial infarction

Crit Pathw Cardiol. 2010 Dec;9(4):235-42. doi: 10.1097/HPC.0b013e31820303ff.

Abstract

Our understanding and treatment of the ST-elevation myocardial infarction (STEMI) has led to a tremendous improvement in the care and preservation of life affecting millions yearly. As the medical community continues to discover novel strategies in therapeutics and innovations in prevention, it is imperative to understand the scientific journey the treatment of STEMI has traveled. Furthermore, the research pillars that led to our understanding of the current paradigm of STEMI will be highlighted in an effort to illuminate the foundation on which we now stand.

Publication types

  • Review

MeSH terms

  • Angioplasty, Balloon, Coronary / adverse effects*
  • Animals
  • Coronary Angiography
  • Coronary Vessels / pathology
  • Disease Models, Animal
  • Dogs
  • Drug-Eluting Stents / adverse effects
  • Electrocardiography
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Mortality
  • Myocardial Infarction* / diagnosis
  • Myocardial Infarction* / epidemiology
  • Myocardial Infarction* / physiopathology
  • Myocardial Infarction* / therapy
  • Risk Factors
  • Thromboembolism / drug therapy
  • Thromboembolism / etiology
  • Treatment Outcome

Substances

  • Fibrinolytic Agents